Share on StockTwits
 

Shares of BTG (LON:BTG) have earned an average recommendation of “Hold” from the eleven analysts that are covering the stock, Stock Ratings Network reports. Three investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is GBX 524.78 ($8.79).

BTG (LON:BTG) traded down 0.67% during mid-day trading on Thursday, hitting GBX 596.50. The stock had a trading volume of 295,715 shares. BTG has a 1-year low of GBX 321.792 and a 1-year high of GBX 624.00. The stock’s 50-day moving average is GBX 592.7 and its 200-day moving average is GBX 473.9.

A number of analysts have recently weighed in on BTG shares. Analysts at N+1 Singer reiterated a “sell” rating on shares of BTG in a research note on Wednesday, January 29th. They now have a GBX 490 ($8.21) price target on the stock. Separately, analysts at Nplus1 Brewin reiterated a “sell” rating on shares of BTG in a research note on Wednesday, January 29th. They now have a GBX 490 ($8.21) price target on the stock. Finally, analysts at FinnCap reiterated a “sell” rating on shares of BTG in a research note on Wednesday, January 29th. They now have a GBX 345 ($5.78) price target on the stock.

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.